استمتع بـUnlimited مع Magzter GOLD

استمتع بـUnlimited مع Magzter GOLD

احصل على وصول غير محدود إلى أكثر من 9000 مجلة وصحيفة وقصة مميزة مقابل

$149.99
 
$74.99/سنة

يحاول ذهب - حر

India is a strategically important market for Optima and this is why we are increasing our footprint here

May 2025

|

Express Pharma

Optima recently acquired the Global Competence Centre (GCC) of Pune-based Eckstein Engineering — a strategic move to significantly enhance Optima India's engineering, manufacturing and service capabilities. In an exclusive interaction, Stefan König, CEO, Optima, and Christoph Müller, Managing Director, Optima, share details about the company's three-decade journey in the pharma sector and its expanding footprint in India. They also delve into Optima’s focus on delivering end-to-end turnkey solutions, advancing sustainability goals, and leveraging India's distinct market dynamics, with Lakshmipriya Nair

India is a strategically important market for Optima and this is why we are increasing our footprint here

Can you take us through Optima’s evolution? And, what are the major transformations that the pharma and biotech industries have seen since Optima's inception?

Stefan König:

The Optima story in pharma started about 30 years ago. At that time, it was mainly about syringe filling with high quality results. Then there was rapid development in requirements - regulations emerged, quality standards increased, and 100% IPC weight control became essential.

The next major shift was the growing importance of isolators. We addressed this by acquiring a company specialised in both filling machines and isolators. Various containers gained prominence, like cartridges, which have become significant in recent years, while ampoules have declined in usage. Now we're in a phase with many new therapies emerging - biobased pharmaceuticals, weight reduction medications, cell and gene therapies, etc.

For us, this means delivering complete turnkey lines is the best way to support our customers.

Can you share more about Optima’s journey in India?

Christoph Müller:

We entered the Indian market with our own setup in 2011, so we've been operating here for quite some time. We started with a classical sales approach with just one person. This person, Akshay Chikodi, is now the Managing Director of Optima Machinery India.

Over the years, both fortunately and through the hard work of our teams in India and Germany, we've managed to sell equipment to the rapidly growing Indian market. We've also been able to grow alongside the company. Beyond pure sales activities, we've expanded to offer comprehensive after-sales services to our customers.

So, who are your major clients at Optima?

Müller:

We have a broad base of clients here in India and I think one big milestone is that we just recently sold our first turnkey line to the Indian market.

المزيد من القصص من Express Pharma

Express Pharma

Express Pharma

Flexotherm Heating Tapes & Cords

Typical Applications of Heating Tapes and Cords in Industrial Solvent Handling

time to read

1 mins

October 2025

Express Pharma

Express Pharma

DRIVING INDIA'S INNOVATION EDGE

Pharma leaders come together to highlight Bengaluru's R&D strength, tech ecosystem, and talent pool to power India Pharma Inc's shift from generics to innovation and global leadership

time to read

16 mins

October 2025

Express Pharma

Express Pharma

Al compass: Transforming pharma commercialisation

As the world evolves at a rapid pace, pharma companies are embracing smarter approaches, leveraging Al across nearly every aspect of commercialisation, from market forecasting and personalised marketing to dynamic pricing and beyond. In this article, Neha Aathavale takes the pulse of the industry to explore who is taking note and how companies are beginning to put Al into action in their commercial operations

time to read

7 mins

October 2025

Express Pharma

Express Pharma

PRIME NEO: New age doors from Gandhi Automation

Gandhi Automations presents the multi-composites, high-performance door PRIME NEO for clean environments. Complete Washable, Greater Sealing and Pressure Resistant.

time to read

1 mins

October 2025

Express Pharma

Express Pharma

Unani Medicine: At crossroads of tradition and modernity

Manufacturers, academic institutions and research councils are working together to elevate Unani medicine through clinical validation and policy alignment with international standards, finds Swati Rana

time to read

7 mins

October 2025

Express Pharma

Express Pharma

Single-Use Technologies in Biologics Manufacturing: Benefits, Challenges, and Growing Demand

The biopharmaceutical industry is increasingly adopting single-use technology (SUT) to achieve flexibility, cost efficiency, and faster time-to-market. Compared with stainless steel systems, SUT reduces capital investment, eliminates cleaning and sterilization steps, lowers contamination risk, and shortens production timelines.

time to read

1 min

October 2025

Express Pharma

Express Pharma

Sustainable packaging with Romaco and Liveo Research

Recycable blister packs

time to read

3 mins

October 2025

Express Pharma

Express Pharma

With India soon to be three times the population of the EU, it makes perfect sense to have manufacturing here

As part of Sweden's Focus Asia programme, a high-level SME delegation recently visited India to strengthen bilateral ties and explore collaborations across sectors including pharma, biotech and others. Building on the momentum of the \"Time for Sweden\" event, the visit underscored Sweden's commitment to innovation, sustainability, and co-creation with India. Among the delegation was Emil Alexander Byström, CEO of SpinChem AB, who in an interaction with Kalyani Sharma shared his insights on how advanced Swedish technologies like biocatalysis and the company's patented Rotating Bed Reactor (RBR) can accelerate India's pharma and biotech innovation journey while supporting sustainable growth.

time to read

3 mins

October 2025

Express Pharma

Express Pharma

Cell therapy's next chapter: Industry embraces in-vivo innovation

Nikhil C Bhanumathi, Principal Clinical Lead, Thermo Fisher Scientific highlights that cell therapy is entering a bold new phase in 2025 as the industry shifts from complex, lab-based ex vivo CAR-T to faster, more accessible in vivo CAR-T innovations. This approach promises to expand access, lower costs, and potentially tackle solid tumors and autoimmune diseases

time to read

4 mins

October 2025

Express Pharma

Express Pharma

Research misconduct ...can delay meaningful and reliable discoveries

Dr Gráinne McNamara, Research Integrity/Publication Ethics Manager, S. Karger AG explores how research misconduct, peer review fraud slow down pharma research. Of particular concern to India is the fact that India-based researchers constitute 5 per cent of articles in life sciences retracted between 1976-2023. India-based researchers also have one of the highest rates of retraction relative to the overall publication output. Over an email exchange with Viveka Roychowdhury, she details how publishers are now deploying AI tools, some of which contributed to the problem in the first place, to detect and avert fraudulent research submissions

time to read

6 mins

October 2025

Listen

Translate

Share

-
+

Change font size